Table 1 Studies on kidney diseases using siRNAs

Yang et al.

Porcine LLC-PK1

-

Cationic lipid

In vitro

Caspase-3

Apoptosis

[25]

Yang et al.

Porcine

-

UW solution

Ex vivo, renal artery injection and autologous blood perfusate

Caspase-3

Apoptosis

[22]

Yang et al.

Porcine

-

UW solution

In vivo, renal artery injection

Caspase-3

Apoptosis

[14]

Yang et al.

Porcine

LNA

UW solution

In vivo, renal artery injection and systemically iv.

Caspase-3

Apoptosis

[18]

Liu et al.

Mice

-

Plasmid

In vivo, hydrodynamic injection iv.

TLR9

Innate immunity

[48]

Hamar et al.

Mice

2’-O-ACE-RNA phosphoramidites

Phosphate buffered saline

In vivo, hydrodynamic injection iv.

Fas

Apoptosis

[28]

Wan et al.

Rats

-

Phosphate buffered saline

In vivo, renal artery injection

IKKβ

Inflammation

[27]

Xia et al.

Mice

-

Cationized gelatin microspheres

In vivo, injected via ureter

HSP47

collagen-producing, fibrosis

[29]

Molitoris et al.

Rats

2’O-methylation

Lipofectamine 2000

In vivo, iv.

p53

Apoptosis

[37]

Zheng et al.

Mice

-

Lipofectamine 2000

In vivo, hydrodynamic injection iv.

Complement 3 and caspases-3

Complement and apoptosis

[38]

Shimizu et al.

Mice

-

Nanocarrier complexation

In vivo, ip.

MAPK1

Immunity

[49]

Shang et al.

ACHN, A498 RCC cells

-

Lipofectamine 2000

In vitro

HIF-1α, HIF-2α

Tumorigenesis

[53]

Juengel et al.

Caki-1 RCC cells

-

Transfection reagent supplied by Qiagen

In vitro

HDAC1, HDAC2

Acetylation

[54]

Fujino et al.

Mice

-

Cationic lipid

In vivo, renal artery injection

p53

Apoptosis

[46]